Leerink analyst Mani Foroohar lowered the firm’s price target on Lexeo Therapeutics (LXEO) to $18 from $20 and keeps an Outperform rating on the shares. The firm notes the company announced a secondary offering and concurrent private placement with gross proceeds of $135M, alongside additional LX2020 PKP2 data. Leerink says that shoring up the balance sheet ahead of pivotal FACM trial initiation and additional PKP2 data makes sense to the firm, and keeps the focus on Lexeo’s data rather than any balance sheet overhang.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LXEO:
- Lexeo Therapeutics 15.625M share Spot Secondary priced at $8.00
- Lexeo announces common stock and warrants offering, no amount given
- 3 Best Stocks to Buy Now, 10/15/2025, According to Top Analysts
- Lexeo Therapeutics initiated with a Buy at Guggenheim
- Buy Rating for Lexeo Therapeutics Driven by Regulatory Progress and Promising Clinical Data on LX2006